We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

1 hedge funds and large institutions have $1K invested in POINT Biopharma Global Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

18,472% more call options, than puts

Call options by funds: $8.54M | Put options by funds: $46K

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 124

99% less funds holding

Funds holding: 125 → 1 (-124)

100% less capital invested

Capital invested by funds: $411M → $1K (-$411M)

Holders
1
Holders Change
-124
Holders Change %
-99.2%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
124
Calls
$8.54M
Puts
$46K
Net Calls
+$8.5M
Net Calls Change
+$9.58M

Top Buyers

Rank Fund Capital Flow
1
BTI
Blue Trust Inc
Georgia
+$1.65K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$70.5M
2
BlackRock
BlackRock
New York
-$44.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$31.1M
4
State Street
State Street
Massachusetts
-$23.5M
5
GPP
Great Point Partners
Connecticut
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
101
GSA Capital Partners
United Kingdom
– -$93K -13,987 Closed
ProShare Advisors
102
ProShare Advisors
Maryland
– -$78.4K -11,754 Closed
Lazard Asset Management
103
Lazard Asset Management
New York
– -$77K -11,704 Closed
EFM
104
E Fund Management
China
– -$76K -11,463 Closed
Zurich Cantonal Bank
105
Zurich Cantonal Bank
Switzerland
– -$74.1K -11,114 Closed
CA
106
Claro Advisors
Massachusetts
– -$72.8K -10,920 Closed
CHAM
107
Clear Harbor Asset Management
Connecticut
– -$66.7K -10,000 Closed
VEA
108
Virtus ETF Advisers
New York
– -$66.4K -9,954 Closed
DekaBank Deutsche Girozentrale
109
DekaBank Deutsche Girozentrale
Germany
– -$61K -9,092 Closed
AIP
110
Ameritas Investment Partners
Nebraska
– -$60K -8,990 Closed
AB
111
Amalgamated Bank
New York
– -$59K -8,845 Closed
Russell Investments Group
112
Russell Investments Group
United Kingdom
– -$54.2K -8,128 Closed
MLICM
113
Metropolitan Life Insurance Company (MetLife)
New York
– -$39.5K -5,920 Closed
SOW
114
State of Wyoming
Wyoming
– -$28.1K -4,206 Closed
TRCT
115
Tower Research Capital (TRC)
New York
– -$17.5K -2,624 Closed
Fidelity Investments
116
Fidelity Investments
Massachusetts
– -$11.5K -1,717 Closed
FCA
117
FinTrust Capital Advisors
South Carolina
– -$6.67K -1,000 Closed
S
118
SignatureFD
Georgia
– -$5.8K -870 Closed
Osaic Holdings
119
Osaic Holdings
Arizona
– -$4.01K -601 Closed
Toronto Dominion Bank
120
Toronto Dominion Bank
Ontario, Canada
– -$894 -134 Closed
Carson Wealth (CWM LLC)
121
Carson Wealth (CWM LLC)
Nebraska
– -$1K -117 Closed
US Bancorp
122
US Bancorp
Minnesota
– -$594 -89 Closed
Nisa Investment Advisors
123
Nisa Investment Advisors
Missouri
– -$200 -30 Closed
MFG
124
Mendota Financial Group
Wisconsin
– -$7 -1 Closed
1 2 3 4
5

PNT Hedge Fund Activity: Q4 2023 in Review

1 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2023, worth a combined $1K — down 100% from $411M a quarter earlier.

Sellers outnumbered buyers: 124 funds closed out of PNT and 1 opened new positions — a net loss of 123 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Blue Trust Inc, opening a new position worth an estimated $1.65K. The largest seller was BVF Inc, exiting entirely with an estimated $70.5M sold.

  • 1 institutional investor held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2023, down from 125 in Q3 2023.
  • Funds reported $1K of POINT Biopharma Global Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 1 fund opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2023 and 124 closed out, a net change of -123 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2023 was Blue Trust Inc, an estimated $1.65K added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2023 was BVF Inc, an estimated $70.5M sold.

Based on aggregated 13F filings for Q4 2023.